BOCS

BOCS identifies genetic biomarkers by scoring DNA k-mer content (A-G-C-T) using a label-free, content-based sequencing approach that probabilistically maps k-mer profiles to gene sequences for rapid, massively parallel detection and inherent data compression.

Key Features:

• Content-Based Sequence Alignment: Uses content-based sequence alignment to probabilistically map k-mer contents to gene sequences within a biomarker database and produce probability rankings based on content scores.
• DNA k-mer Analysis (A-G-C-T): Scores DNA k-mer content specifically focusing on the A-G-C-T nucleotide composition for biomarker identification.
• Label-Free Detection and Data Compression: Operates as a label-free detection method and provides inherent data compression capabilities.
• Massively Parallel Acquisition: Supports massively parallel data acquisition for high-throughput analysis.
• High Accuracy in Biomarker Detection: Simulation results report 100% accuracy without sequencing errors and over 90% accuracy with up to 20% sequencing errors, and 100% accuracy for multiple resistance genes in MRSA at an average gene coverage of 0.515 with a 4% sequencing error rate.
• Scalability and Versatility: Extends to diverse genetic contexts including cancer and other genetic disorders with performance comparable to resistance gene detection.

Scientific Applications:

• Antibiotic Resistance Detection: Identification of single and multiple antibiotic resistance genes, with demonstrated performance on methicillin-resistant Staphylococcus aureus (MRSA) simulations.
• Precision Medicine Diagnostics: Rapid genetic biomarker profiling for applications in antibiotic resistance, cancer, and other genetic diseases to inform diagnostic and treatment decisions.

Methodology:

BOCS computes DNA k-mer content (A-G-C-T), applies content-based sequence alignment to probabilistically map k-mer profiles to gene sequences in a biomarker database, and ranks genes by probability based on content scores.